Protein kinase Erk3 plays a critical role in intrauterine growth and lung maturation
October 26, 2015
Significant, double-digit blood pressure reductions were observed in both treatment arms (133/76 mmHg in both arms at study end). However, compared to the non-ARB-based therapy group, significantly fewer individuals in the Diovan* add-on group experienced a primary endpoint, Hazard Ratio (HR) =0.55,>
The KYOTO HEART study was conceived designed and conducted by an independent steering committee, representing the Kyoto Prefectural University School of Medicine, and was funded by the Kyoto Foundation for the Promotion of Medical Science. Novartis Pharmaceuticals Canada Inc. had no role in the study's conception or design, or in carrying out the study, including data collection, data analysis, data planning or data interpretation, or in the writing of the study report.
Novartis Pharma K.K. Japan has already made several research grants to the Kyoto Prefectural University School of Medicine.
Cardiovascular disease and stroke in Canada
Cardiovascular disease accounts for the death of more Canadians than any other disease. In 2005 (the latest year for which Statistics Canada has data), cardiovascular disease accounted for more than 71,000 Canadian deaths: 54% of all cardiovascular deaths are due to ischemic heart disease; 20% to stroke and 24% to heart attack.(3)
In Canada, stroke is the third most common cause of death. More than 50,000 Canadians suffer from a stroke each year, resulting in approximately 14,000 deaths. Of these sufferers, 40% are left with a moderate to severe impairment, while 10% are so severely disabled they require long-term care.(3)
According to Statistics Canada, Canadians of Asian ancestry comprise the largest visible minority in the country, at 11% of the population, and is the fastest growing. Most Asian Canadians are concentrated in urban areas of southern Ontario, the Greater Vancouver area, Montreal, and other large Canadian cities.(4)
Source: NOVARTIS PHARMACEUTICALS CANADA INC.